Skip to content

Evaluation of a Novel Human Milk Fortifier in Preterm Infants

Evaluation of a Novel Human Milk Fortifier in Preterm Infants

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01373073
Enrollment
147
Registered
2011-06-14
Start date
2011-08-31
Completion date
2012-12-31
Last updated
2013-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Infants

Brief summary

The purpose of this study is to assess growth of preterm infants fed human milk supplemented with an experimental human milk fortifier.

Interventions

OTHERExperimental human milk fortifier

Human milk fortifier to be added to human milk feedings

OTHERControl human milk fortifier

Control human milk fortifier to be added to human milk

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 21 Days
Healthy volunteers
No

Inclusion criteria

* 700-1500g birth weight * 33 weeks or less gestational age * Appropriate for gestational age * Initiate enteral feeds of human milk by 21 days of life * Mother provided exclusive human milk feeds * Parents allow both human milk and study human milk fortifier * Singleton or twin birth

Exclusion criteria

* Feeding preterm infant formula or non-study human milk fortifier * Expected at facility less than 15 days * Congenital anomalies/disease affecting growth and development * 5 minute APGAR of 4 or less * Steroid use * ECMO * Grade III or IV PVH/IVH * Mechanical ventilator dependency * Maternal incapacity * History of major surgery * Asphyxia * Confirmed NEC or sepsis * Use of probiotics

Design outcomes

Primary

MeasureTime frame
Weight gain29 days

Secondary

MeasureTime frameDescription
Anthropometric variables29 daysLength and head circumference
GI tolerance29 daysstool characteristics, periods of nil per os (NPO), and withheld feedings due to abdominal distention, gastric residuals, vomiting, etc.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026